Literature DB >> 2136982

Screening for hypertension.

B Littenberg1, A M Garber, H C Sox.   

Abstract

PURPOSE: To review the evidence on four questions about screening asymptomatic adults for arterial hypertension: Is hypertension a significant health problem? Is it detectable at an early, presymptomatic stage? Is treatment available and effective? Do the benefits of screening outweigh the costs and risks? DATA IDENTIFICATION AND SELECTION: We did a computerized search of the MEDLARS data base to identify community-based trials of drug therapy for mild hypertension; other relevant citations are included when appropriate. DATA SYNTHESIS: We approached the preliminary questions in our analysis by narrative review and argument. The estimates of therapeutic efficacy are based on previously published meta-analyses. The cost-effectiveness of screening was addressed by formal mathematical modeling of the effect of screening on various U.S. populations. RESULTS OF ANALYSIS: Hypertension is clearly a significant health problem. It can be detected early, and effective treatment is available. Screening asymptomatic adults for hypertension has benefits that compare favorably to the risks and costs involved. According to our estimates, screening is most cost-effective for older adults compared with younger adults and for men compared with women and is highly sensitive to the cost of therapy for mild hypertension.
CONCLUSIONS: We recommend hypertension screening for all adults. We also discuss the frequency and setting of screening activities. When a low-cost therapy is used, the cost-effectiveness of screening for hypertension compares favorably with other cardiovascular interventions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2136982     DOI: 10.7326/0003-4819-112-3-192

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

1.  Does over-the-counter nicotine replacement therapy improve smokers' life expectancy?

Authors:  W F Lawrence; S S Smith; T B Baker; M C Fiore
Journal:  Tob Control       Date:  1998       Impact factor: 7.552

2.  Pitfalls in the interpretation of pharmacoeconomic studies.

Authors:  N M Kaplan
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

Review 3.  Economic factors in the initiation of antihypertensive therapy.

Authors:  I Kawachi
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

4.  Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors.

Authors:  Yasuaki Hayashino; Sizuko Nagata-Kobayashi; Takeshi Morimoto; Kenji Maeda; Takuro Shimbo; Tsuguya Fukui
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

Review 5.  Interpretation of cost-effectiveness analyses.

Authors:  D K Owens
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

6.  Choosing antihypertensive therapy.

Authors:  D A Katzman; B Littenberg
Journal:  J Gen Intern Med       Date:  1995-12       Impact factor: 5.128

Review 7.  Surgical, interventional, and device innovations in the management of hypertension.

Authors:  Sibu P Saha; Khaled M Ziada; Thomas F Whayne
Journal:  Int J Angiol       Date:  2015-03

Review 8.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

9.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 10.  Economics of hypertension control. World Hypertension League.

Authors: 
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.